Elixir Medical Clinical Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study "EXCELLA II STUDY"

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

360 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-10-31

Study Completion Date

2014-03-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized Study To evaluate the safety and effectiveness of the Elixir Medical DESyne Novolimus-Eluting Coronary Stent System with Durable Polymer through the assessment of clinical, angiographic and IVUS endpoints as compared to the concurrently enrolled Medtronic Zotarolimus-Eluting Coronary Stent System in a randomized, single blind study of up to 200 male and female patients. In a Continued Access Registry of up to 100 patients receiving the DESyne Stent clinical-only endpoints will be evaluated.

To evaluate the safety and effectiveness of the Elixir Novolimus-Eluting Coronary Stent System with bioabsorbable polymer as compared to the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System control through clinical and angiographic endpoints.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

EXCELLA Post-Approval Study

NCT02009956

Coronary Artery Disease

COMPLETED NA

EXCEL-II Stent Vesus EXCEL Stent to Treat the Patients With de Novo Coronary Artery Lesions.

NCT02057978

Coronary Artery Disease Myocardial Ischemia Coronary Disease +5 more

COMPLETED

The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries

NCT04192747

Coronary Artery Disease Coronary Artery Stenosis Coronary Disease +1 more

ACTIVE_NOT_RECRUITING NA

Clinical Investigation of the MiStent Drug Eluting Stent (DES) in Coronary Artery Disease

NCT01294748

Coronary Artery Disease

COMPLETED PHASE2

Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial

NCT02086045

Coronary Artery Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1. DESyne DES

Test arm: Intervention with DESyne Novolimus-Eluting Coronary Stent DESyne Novolimus Stent System

Group Type EXPERIMENTAL

DESyne Novolimus Stent System

Intervention Type DEVICE

coronary stent implantation

2. Medtronic Endeavor DES

Control arm: Intervention with Medtronic Endeavor Zotarolimus-Eluting Coronary Stent Medtronic Endeavor Coronary Stent System

Group Type ACTIVE_COMPARATOR

Medtronic Endeavor Coronary Stent System

Intervention Type DEVICE

coronary stent implantation

3. DESyne BD DES

Test arm: Intervention with DESyne BD Novolimus-Eluting Coronary Stent DESyne BD Novolimus Stent System

Group Type EXPERIMENTAL

DESyne BD Novolimus Stent System

Intervention Type DEVICE

coronary stent implantation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medtronic Endeavor Coronary Stent System

coronary stent implantation

Intervention Type DEVICE

DESyne BD Novolimus Stent System

coronary stent implantation

Intervention Type DEVICE

DESyne Novolimus Stent System

coronary stent implantation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient has a planned intervention of a single lesion in one or two separate major epicardial territories. Each lesion/vessel must meet the following criteria:
* De novo
* The target lesion reference site must be visually estimated to be \> 2.5 mm and \< 3.5 mm in diameter.
* The target vessel must be a major coronary artery or major branch with a visually estimated stenosis of \> 50% and \<100%.
* The visually estimated target lesion must be able to be covered by a single, 14, 18 or 28mm stent Elixir Stent or a single 14, 18, 24 or 30mm Endeavor Stent. Note that the 8mm Endeavor Stent will not be used in this study.
* Maximum lesion length is 24 mm.
* \> TIMI 1 coronary flow.

Exclusion Criteria

* The patient has a known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, mTOR inhibitor class drugs, cobalt chromium alloy, methacrylate or polylactide polymer, or sensitivity to contrast which cannot be adequately premedicated.
* There will be an untreated significant lesion of \> 40% diameter stenosis remaining proximal or distal to the target site after the planned intervention.
* Total occlusion or TIMI 0 coronary flow in the target vessel.
* Restenosis lesion
* The proximal target vessel or target lesion is severely calcified by visual assessment.
* Aorto-ostial location, unprotected left main lesion location, or a lesion within 5 mm of the origin of the LAD or LCX.
* Lesion involvement of a significant side branch (branch diameter \> 2 mm) that would be covered by stenting.
* The patient has suffered a myocardial infarction with total creatine kinase (CK) \>2 times normal within the past 72 hours (exactly three days).
* The patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
* The patient suffered a stroke, transient ischemic neurological attack (TIA) or significant gastrointestinal (GI) bleed within the past six months.
* The patient has renal insufficiency as determined by a creatinine of \> 2.0mg/dl.
* The target lesion, or the target vessel proximal to the target lesion, contains thrombus.
* Documented left ventricular ejection fraction of \< 25%.
* The patient is a recipient of a heart transplant.
* The patient has extensive peripheral vascular disease that precludes safe 6 French sheath insertion or extreme anti-coagulation.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No